Idexx Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced an increase in its ongoing share repurchase program. The company's board of directors has authorized the repurchase of up to five million additional shares of the company's common stock. This authorization is in addition to the 1.3 million shares remaining under the company's ongoing share repurchase program as of December 3, 2024, pursuant to previous board authorizations.
Idexx Laboratories, Inc. is known for its diagnostic and software products and services that create clarity in the complex, constantly evolving world of veterinary medicine. The company supports longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions. Idexx Laboratories, Inc. also plays a role in ensuring the safety of milk and water across the world and maintaining the health and well-being of people and livestock.
Headquartered in Maine, Idexx employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. The share repurchase program has no specified expiration date and may be suspended or discontinued at any time, and repurchases may be made at management's discretion from time to time in the open market or in negotiated transactions. Following these announcements, the company's shares moved 3.0%, and are now trading at a price of $448.95. For the full picture, make sure to review IDEXX Laboratories's 8-K report.
